Quetiapine for the treatment of generalised anxiety disorder
Please note that following on from information provided to NICE by the company in February 2011, the appraisal of Quetiapine for the treatment of generalised anxiety disorder [ID347] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 347
- Referral date:
- 01 June 2010
- Topic area
- Mental health and behavioural conditions, Public health
Provisional Schedule
- Closing date for invited submissions / evidence submission::
- 9 December 2010
- 1st appraisal committee meeting::
- TBC
Project Team
- Communications manager:
- Alice Law
- Executive Lead:
- Andrew Dillon
- Project manager:
- Liz Walker
- Technical Lead:
- Raisa Sidhu
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in February 2011, the appraisal of Quetiapine for the treatment of generalised anxiety disorder [ID347] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
For further information on our processes and methods, please see our CHTE processes and methods manual